336 Results for "

VHL E3

" in MedChemExpress (MCE) Product Catalog:
Products (336)

336 Results for "VHL E3" in MCE Product Catalog:

17
17 Publications Verification
Cat. No.: HY-100947
CAS No.: 2097381-85-4
Pureté:  99.54%
VH-298 is a highly potent inhibitor of the VHL:HIF-α interaction with a Kd value of 80 to 90 nM. VH-298 leads to HIF-α accumulation inside HeLa cells. VH-298 is an E3 ligase Ligand, and can be used for synthesis of PROTACs .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-130604
CAS No.: 2365172-42-3
Pureté:  99.61%
Domaines de recherche:  

Inflammation/Immunology Cancer

DT2216 is a potent and selective BCL-XL (Bcl-2 family member) degrader based on PROTAC technology. DT2216 causes effective degradation of BCL-XL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. DT2216 inhibits various BCL-XL-dependent leukemia and cancer cells but considerably less toxic to platelets .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-103604
CAS No.: 2064292-52-8
Pureté:  98.06%
Synonyms: VH032-PEG4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 4 hydrochloride; E3 ligase Ligand-Linker Conjugates 7
Domaines de recherche:  

Cancer

(S,R,S)-AHPC-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-103601
CAS No.: 1797406-81-5
Pureté:  99.93%
Synonyms: VH032-PEG4-N3; VHL Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 4
Domaines de recherche:  

Others

(S,R,S)-AHPC-PEG4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. (S,R,S)-AHPC-PEG4-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-103604A
CAS No.: 2010159-57-4
Pureté:  95.62%
Synonyms: VH032-PEG4-NH2; VHL Ligand-Linker Conjugates 4 ; E3 ligase Ligand-Linker Conjugates 7 Free Base
Domaines de recherche:  

Cancer

(S,R,S)-AHPC-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-131295
CAS No.: 2581116-22-3
Pureté:  98.62%
Domaines de recherche:  

Cancer

PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-132296
CAS No.: 2743427-26-9
Pureté:  99.26%
Target:  

FAK PROTACs

Domaines de recherche:  

Cancer

GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-114322
CAS No.: 2306193-61-1
Pureté:  98.00%
Domaines de recherche:  

Cancer

VZ185 is a BRD9 and BRD7 PROTAC degrader, with DC50 values of 1.76 nM and 4.5 nM, respectively, in RI-1 cells; and DC50 values of 4 nM and 34 nM, respectively, in HEK293 cells. VZ185 hijacks the CRL2 VHL E3 ubiquitin ligase complex to induce ubiquitination and subsequent proteasomal degradation of BRD9 and BRD7. VZ185 can be used in research related to acute myeloid eosinophilic leukemia and malignant rhabdoid tumors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-137516
CAS No.: 2502156-03-6
Pureté:  98.16%
Target:  

PROTACs Ras

Domaines de recherche:  

Cancer

LC-2 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC50s between 0.25 and 0.76 μM . LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-112495
CAS No.: 1799506-06-1
Pureté:  99.93%
Synonyms: HaloPROTAC 2
Domaines de recherche:  

Cancer

VH032-PEG5-C6-Cl (HaloPROTAC 2) is a conjugate of ligands for E3 and 21-atom-length linker. The connector of linker is Halogen group. VH032-PEG5-C6-Cl incorporates the VH032 based VHL ligand and 5-unit PEG linker. VH032-PEG5-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-111997
CAS No.: 1799506-07-2
Pureté:  96.49%
Synonyms: HaloPROTAC 3
Domaines de recherche:  

Others

VH285-PEG4-C4-Cl (HaloPROTAC 3) is a conjugate of ligands for E3 and 16-atom-length linker. The connector of linker is Halogen group. VH285-PEG4-C4-Cl incorporates the VH285 based VHL ligand and an alkyl/ether-based linker. VH285-PEG4-C4-Cl is a highly potent and efficacious degrader of GFP-HaloTag7 with a DC50 of 19 nM. VH285-PEG4-C4-Cl is able to induce 90 % degradation of GFP-Halotag at 625 nM. VH285-PEG4-C4-Cl binds to VHL with an IC50 of 0.54 μM .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-145479
CAS No.: 2767440-24-2
Pureté:  98.19%
Domaines de recherche:  

Cancer

PROTAC AR-V7 degrader-1 is a selective AR-V7 degrader with a DC50 of 0.32 μM. PROTAC AR-V7 degrader-1 inhibits cancer cell proliferation. PROTAC AR-V7 degrader-1 is applicable to the research of castration-resistant prostate cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-125905
CAS No.: 2306193-99-5
Pureté:  99.92%
Synonyms: VHL ligand 3; E3 ligase Ligand 19
Target:  

Ligands for E3 Ligase

Domaines de recherche:  

Cancer

VH032-cyclopropane-F is the VH032-based VHL ligand. VH032-cyclopropane-F can be connected to the ligand for protein (e.g., SMARCA BD ligand) by a linker to form PROTACs (e.g., PROTAC 1). PROTAC 1 is a partial degrader of SMARCA2 and SMARCA4 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136262
CAS No.: 2362575-45-7
Pureté:  98.97%
Target:  

PROTACs E1/E2/E3 Enzyme

Domaines de recherche:  

Cancer

CRBN-6-5-5-VHL is a potent and selective VHL E3 ligand-based Cereblon (CRBN) PROTAC degrader with a DC50 value of 1.5 nM. CRBN-6-5-5-VHL forms a heterotrimeric complex with CRBN and VHL E3 ligase, thereby promoting CRBN ubiquitination and proteasomal degradation without inducing VHL degradation. CRBN-6-5-5-VHL protects myeloma from the toxic effects of IMiDs. CRBN-6-5-5-VHL can be used in the research of multiple myeloma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-103599
CAS No.: 2010159-45-0
Pureté:  99.94%
Synonyms: VH032-PEG2-N3; VHL Ligand-Linker Conjugates 6; E3 ligase Ligand-Linker Conjugates 13
Domaines de recherche:  

Cancer

(S,R,S)-AHPC-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-PEG2-N3 can be used for the synthesis of PROTACs .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-103605
CAS No.: 1835705-55-9
Pureté:  97.01%
Synonyms: VH032-C6-PEG3-C4-Cl; VHL Ligand-Linker Conjugates 12; E3 ligase Ligand-Linker Conjugates 8
Domaines de recherche:  

Cancer

(S,R,S)-AHPC-C6-PEG3-C4-Cl (VH032-C6-PEG3-C4-Cl) is a conjugate of ligands for E3 and 20-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-C6-PEG3-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and an alkyl/ether-based linker. (S,R,S)-AHPC-C6-PEG3-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-103607
CAS No.: 1835705-57-1
Pureté:  98.21%
Synonyms: VH032-PEG2-C4-Cl; VHL Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 10
Domaines de recherche:  

Cancer

(S,R,S)-AHPC-PEG2-C4-Cl (VH032-PEG2-C4-Cl) is a conjugate of ligands for E3 and 13-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-PEG2-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and an alkyl/ether-based linker. (S,R,S)-AHPC-PEG2-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145816A
JPS016 TFA is a class I histone deacetylase (HDAC) PROTAC inhibitor. JPS016 TFA recruits the VHL E3 ligase (Ligands for E3 Ligase) to mediate the ubiquitination and proteasomal degradation of HDAC1, HDAC2 and HDAC3. JPS016 TFA reduces the viability of colon cancer cells and induces Apoptosis. JPS016 TFA activates the PINK1/Parkin mitochondrial Autophagy pathway, enhances cardiomyocyte viability, alleviates mitochondrial damage, and reduces mitochondrial ROS production in cells. JPS016 TFA is applicable to research related to colon cancer and sepsis cardiomyopathy .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-148771
CAS No.: 2488296-74-6
Pureté:  99.79%
Synonyms: PROTAC AR-V7 degrader-2
Domaines de recherche:  

Cancer

MTX-23 is a PROTAC degrader targeting androgen receptor splice variant 7 (AR-V7) and full-length androgen receptor (AR-FL), with DC50 values of 0.37 μM and 2 μM, respectively. MTX-23 binds to the DNA-binding domains of AR-V7 and AR-FL, recruits the VHL E3 ubiquitin ligase (E3 ubiquitin ligase) and induces their degradation. MTX-23 reduces the proliferation of prostate cancer cells, promotes their apoptosis (apoptosis), and also inhibits tumor growth in mouse models. MTX-23 can be used for the research of prostate cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-164233
CAS No.: 2742732-92-7
Target:  

PROTACs HDAC Apoptosis

Domaines de recherche:  

Cancer

YX968 is a selective HDAC3/HDAC8 PROTAC dual degrader, with a DC50 value of 1.7 nM against HDAC3 and 6.1 nM against HDAC8. YX968 inhibits cancer cell growth, induces apoptosis, prevents global histone hyperacetylation, and exerts effects via antiproliferative activity. YX968 can be used in research related to triple-negative breast cancer, non-small cell lung cancer, and multiple myeloma .
loading...
    loading...